Why Did SoFi Stock Drop?
Fintech platform SoFi (NASDAQ:SOFI) has stumbled in recent days, selling…
Buy
72
KYMR Quote, Financials, Valuation and Earnings
Last price:
$94.38
Seasonality move
:
7.7%
Day range:
$64.84 - $67.00
52-week range:
$19.45 - $68.80
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
124.87x
P/B ratio:
5.07x
Volume:
392.7K
Avg. volume:
677.1K
1-year change:
51.13%
Market cap:
$4.8B
Revenue:
$47.1M
EPS (TTM):
-$3.60
Analysts' Opinion
-
Consensus RatingKymera Therapeutics, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 18 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $79.23, Kymera Therapeutics, Inc. has an estimated upside of 16.47% from its current price of $66.62.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $65.00 representing -- downside risk from its current price of $66.62.
Fair Value
-
According to the consensus of 18 analysts, Kymera Therapeutics, Inc. has 16.47% upside to fair value with a price target of $79.23 per share.
KYMR vs. S&P 500
-
Over the past 5 trading days, Kymera Therapeutics, Inc. has underperformed the S&P 500 by -0.31% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Kymera Therapeutics, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Kymera Therapeutics, Inc. revenues have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter Kymera Therapeutics, Inc. reported revenues of $2.8M.
Earnings Growth
-
Kymera Therapeutics, Inc. earnings have been falling on a year-over-year basis for 4 quarters in a row. In the most recent quarter Kymera Therapeutics, Inc. reported earnings per share of -$0.94.
Enterprise value:
4.4B
EV / Invested capital:
0.00x
Price / LTM sales:
124.87x
EV / EBIT:
--
EV / Revenue:
99.96x
PEG ratio (5yr expected):
-0.34x
EV / Free cash flow:
-18.99x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$35.5M
Return On Assets:
-28.57%
Net Income Margin (TTM):
-674.81%
Return On Equity:
-33.29%
Return On Invested Capital:
-30.33%
Operating Margin:
-3207.89%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $46.8M | $87.6M | $43.7M | $3.7M | $2.8M | |
| Gross Profit | $43.3M | $81.3M | $35.5M | $1.7M | $615K | |
| Operating Income | -$184.8M | -$195.3M | -$328.4M | -$72.1M | -$88.7M | |
| EBITDA | -$181.3M | -$189M | -$320.2M | -$70.1M | -$86.5M | |
| Diluted EPS | -$2.88 | -$2.33 | -$3.60 | -$0.82 | -$0.94 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $543.7M | $494M | $375.7M | $568.7M | $528.3M | |
| Total Assets | $642.5M | $638.5M | $552.4M | $1B | $1.1B | |
| Current Liabilities | $94.5M | $91.1M | $63.2M | $66.5M | $71.6M | |
| Total Liabilities | $159.3M | $125.6M | $156.8M | $141.9M | $155.8M | |
| Total Equity | $483.1M | $512.9M | $395.5M | $892.9M | $946.3M | |
| Total Debt | $16M | $14.2M | $78.3M | $76.7M | $72.1M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$150.4M | -$124.7M | -$227.9M | -$50.2M | -$27.1M | |
| Cash From Investing | $71.3M | -$453.7M | -$58.1M | -$157.7M | -$235.3M | |
| Cash From Financing | $4.2M | $608M | $288.3M | $250.9M | $39.5M | |
| Free Cash Flow | -$173.6M | -$148.2M | -$230.2M | -$50M | -$27.3M | |
KYMR
Sector
Market Cap
$4.8B
$28.5M
Price % of 52-Week High
--
51.44%
Dividend Yield
0%
0%
Shareholder Yield
-7.11%
-1.33%
1-Year Price Total Return
51.13%
-20.32%
Beta (5-Year)
2.281
0.520
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$66.47
200-day SMA
Buy
Level
$43.96
Bollinger Bands (100)
Buy
Level
43.77 - 61.91
Chaikin Money Flow
Buy
Level
22.3M
20-day SMA
Buy
Level
$64.83
Relative Strength Index (RSI14)
Buy
Level
60.29
ADX Line
Buy
Level
21.3
Williams %R
Neutral
Level
-37.0119
50-day SMA
Buy
Level
$61.21
MACD (12, 26)
Buy
Level
1.78
25-day Aroon Oscillator
Buy
Level
56
On Balance Volume
Neutral
Level
31.9M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (9.6429)
Sell
CA Score
(Annual)
Level (-0.5911)
Buy
Beneish M-Score
(Annual)
Level (-3.9947)
Buy
Momentum Score
Level (8)
Sell
Ohlson Score
Level (1.1835)
Sell
Piotroski F Score
(Annual)
Level (3)
Sell
Quality Ratio Score
Level (3)
Buy
Fundamental Score
Level (5)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Kymera Therapeutics, Inc. is a biopharmaceutical company, which engages in the discovery and development of small molecule therapeutics that degrade disease-causing proteins. The company was founded by Bruce Lee Booth and Nello Mainolfi on September 29, 2015 and is headquartered in Watertown, MA.
Stock Forecast FAQ
In the current month, KYMR has received 18 Buy ratings 0 Hold ratings, and 0 Sell ratings. The KYMR average analyst price target in the past 3 months is $79.23.
-
Where Will Kymera Therapeutics, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Kymera Therapeutics, Inc. share price will rise to $79.23 per share over the next 12 months.
-
What Do Analysts Say About Kymera Therapeutics, Inc.?
Analysts are divided on their view about Kymera Therapeutics, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Kymera Therapeutics, Inc. is a Sell and believe this share price will drop from its current level to $65.00.
-
What Is Kymera Therapeutics, Inc.'s Price Target?
The price target for Kymera Therapeutics, Inc. over the next 1-year time period is forecast to be $79.23 according to 18 Wall Street analysts, 18 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is KYMR A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Kymera Therapeutics, Inc. is a Buy. 18 of 18 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of KYMR?
You can purchase shares of Kymera Therapeutics, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Kymera Therapeutics, Inc. shares.
-
What Is The Kymera Therapeutics, Inc. Share Price Today?
Kymera Therapeutics, Inc. was last trading at $94.38 per share. This represents the most recent stock quote for Kymera Therapeutics, Inc.. Yesterday, Kymera Therapeutics, Inc. closed at $66.62 per share.
-
How To Buy Kymera Therapeutics, Inc. Stock Online?
In order to purchase Kymera Therapeutics, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get KYMR Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
KYMR
Sector
P/E ratio
--
23.75x
PEG ratio
-0.34x
-0.01x
P/B ratio
5.07x
1.83x
Price / LTM sales
124.87x
1.60x
Growth Metrics
KYMR
Sector
Revenue growth
-26.12%
4.85%
Earnings growth
-14.68%
11.11%
Revenue (5-year growth)
74.21%
6.45%
Earnings forecast
-$0.78
-$0.20
Profitability
KYMR
Sector
Profitability FY 2024
$39.7M
$3.6M
Return on invested capital
-30.33%
-30.98%
Return on assets
-28.57%
-27.62%
Return on equity
-33.29%
-36.69%
Earnings Date
Last Earnings Date
Nov
4
Next Earnings Date
Feb
26
Estimated Next Earnings Date
Feb
3
Balance Sheet
KYMR
Sector
Total cash
$505.7M
$27.2M
Short term investments
$368.5M
$25.7M
Total assets
$978M
$79.7M
Long term debt
$72.1M
$4.1M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Robinhood Win AI Investing?
Recently, online brokerage Robinhood (NASDAQ:HOOD) has been focused on introducing…
Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
56
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
81
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Buy
56
SMX alert for Dec 8
SMX (Security Matters) Plc [SMX] is down 59.64% over the past day.
Buy
72
KYMR alert for Dec 8
Kymera Therapeutics, Inc. [KYMR] is up 41.67% over the past day.
Buy
62
PRAX alert for Dec 8
Praxis Precision Medicines, Inc. [PRAX] is up 9.18% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
